A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
A Phase 1a/b Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Adcentrx Therapeutics
- Phone Number: 858-428-9502
- Email: clinicaltrials@adcentrx.com
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope
-
Contact:
- Erin Morones
- Phone Number: 89708 626-218-9708
- Email: emorones@coh.org
-
Santa Monica, California, United States, 90404
- Recruiting
- UCLA
-
Contact:
- Rosa Vazquez
- Phone Number: 16049 310-633-8400
- Email: ravazquez@mednet.ucla.edu
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49546
- Recruiting
- START MidWest
-
Contact:
- Julie Burns
- Phone Number: 616-954-5559
- Email: Julie.burns@startresearch.com
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Recruiting
- University of Minnesota Masonic Cancer Center
-
Contact:
- Patricia Beckman, RN
- Phone Number: 612-624-2620
- Email: ccinfo@umn.edu
-
-
Texas
-
Austin, Texas, United States, 78758
- Recruiting
- NEXT Austin
-
Contact:
- Suhrutha Bushan
- Phone Number: (737) 610-5202
- Email: sbushan@nextoncology.com
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas MD Anderson Cancer Center
-
Contact:
- Jordi Rodon Ahnert, MD, PHD
- Phone Number: 713-792-5603
- Email: jrodon@mdanderson.org
-
-
Utah
-
West Valley City, Utah, United States, 84119
- Recruiting
- START Mountain Region
-
Contact:
- Marie Asay
- Phone Number: 801-907-4770
- Email: Marie.asay@startresearch.com
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Recruiting
- NEXT Virginia
-
Contact:
- Blake Patterson
- Phone Number: (703) 783-4505
- Email: bpatterson@nextoncology.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Phase 1a Dose Escalation: Subjects with histologically confirmed select advanced solid tumors, including metastatic castration resistant prostate cancer (mCRPC), gastric cancer (GC), and non-small cell lung cancer (NSCLC).
- Phase 1b Dose Expansion: Subjects with histologically confirmed prostate adenocarcinoma that is confirmed to be castration resistant (i.e., serum testosterone < 50 ng/dL [< 2.0 nM]) and that is intolerant/resistant to standard of care (SOC) therapies.
- Measurable disease according to RECIST version 1.1 or evaluable disease per PCWG3 for subjects with prostate cancer
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 in 1a; 0-2 in 1b
- Adequate hematologic, liver, and renal function
Exclusion Criteria:
- Active and uncontrolled central nervous system metastases
- Significant cardiovascular disease
- History of another malignancy other than the one for which the subject is being treated on this study within 3 years
- Receipt of any anticancer or investigational therapy within: 5 elimination half-lives or 14 days (whichever is less); 4 weeks for any therapeutic radiopharmaceutical for prostate cancer
- History of (non-infectious) ILD/pneumonitis that required steroids within 2 years of study enrollment, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
- Receiving systemic antimicrobial treatment for active infection; routine antimicrobial prophylaxis is permitted
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Phase 1a Dose Escalation
Increasing doses of ADRX-0405 will be administered to identify the maximum tolerated dose (MTD) and the recommended dose to be used in the Phase 1b part.
|
Antibody Drug Conjugate targeting STEAP1
|
|
Experimental: Phase 1b Dose Expansion
ADRX-0405 will be initially administered at the dose recommended from the Phase 1a part in subjects with previously treated mCRPC.
|
Antibody Drug Conjugate targeting STEAP1
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of adverse events
Time Frame: Until study completion (estimated 2 years)
|
Until study completion (estimated 2 years)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measurement of End of Infusion or observed maximum blood concentration (Ceoi orCmax) of ADRX-0405
Time Frame: Until study completion (estimated 2 years)
|
Measured from pharmacokinetic (PK) blood samples
|
Until study completion (estimated 2 years)
|
|
Measurement of trough concentration (Ctrough) of ADRX-0405
Time Frame: Until study completion (estimated 2 years)
|
Measured from PK blood samples
|
Until study completion (estimated 2 years)
|
|
Measurement of area under the blood concentration-time curve (AUC) of ADRX-0405
Time Frame: Until study completion (estimated 2 years)
|
Measured from PK blood samples
|
Until study completion (estimated 2 years)
|
|
Measurement of partial area under the concentration-time curve after first dose (AUC0-21) of ADRX-0405 and as appropriate
Time Frame: Until study completion (estimated 2 years)
|
Measured from PK blood samples
|
Until study completion (estimated 2 years)
|
|
Measurement of terminal or apparent terminal half-life (t1/2) of ADRX-0405
Time Frame: Until study completion (estimated 2 years)
|
Measured from PK blood samples
|
Until study completion (estimated 2 years)
|
|
Measurement of systemic clearance (CL) and volume of distribution at steady state (Vss) as appropriate of ADRX-0405
Time Frame: Until study completion (estimated 2 years)
|
Measured from PK blood samples
|
Until study completion (estimated 2 years)
|
|
Incidence of anti-drug antibody (ADA) to ADRX-0405
Time Frame: Until study completion (estimated 2 years)
|
Measured from ADA blood samples
|
Until study completion (estimated 2 years)
|
|
Measurement of objective response rate (ORR) per RECIST 1.1
Time Frame: Until study completion (estimated 2 years)
|
Percentage of subjects achieving complete response (CR) or partial response (PR)
|
Until study completion (estimated 2 years)
|
|
ORR per Prostate Cancer Working Group 3 (PCWG3)
Time Frame: Until study completion (estimated 2 years)
|
Percentage of subjects achieving complete response (CR) or partial response (PR)
|
Until study completion (estimated 2 years)
|
|
Measurement of duration of response (DOR)
Time Frame: Until study completion (estimated 2 years)
|
Time from first response until first evidence of disease progression (PD) or death from any cause
|
Until study completion (estimated 2 years)
|
|
Measurement of disease control rate (DCR)
Time Frame: Until study completion (estimated 2 years)
|
Percentage of subjects achieving CR, PR or stable disease (SD)
|
Until study completion (estimated 2 years)
|
|
Measurement of progression free survival (PFS)
Time Frame: Until study completion (estimated 2 years)
|
Time from the start of study drug until first evidence of PD or death from any cause
|
Until study completion (estimated 2 years)
|
|
Measurement of radiographic progression free survival (rPFS)
Time Frame: Until study completion (estimated 2 years)
|
Time from the start of study drug until first radiographic documentation of PD, or death from any cause, whichever comes first
|
Until study completion (estimated 2 years)
|
|
Measurement of overall survival (OS)
Time Frame: Until study completion (estimated 2 years)
|
Time from the start of study drug until death from any cause
|
Until study completion (estimated 2 years)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ADRX-0405-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.